Pharmaceuticals

Politics Leslie Walker and Dan Gorenstein

STAT Plus: The U.S. has relied on cheap, effective generic drugs for 40 years. Now that promise is under threat

First Opinion Tahir Amin and Timi Iwayemi

STAT Plus: 40 doesn’t look good on Hatch-Waxman

Exclusive Rachel Cohrs Zhang

STAT Plus: A mysterious anti ‘Big Pharma’ bus is barnstorming swing states

Politics John Wilkerson

STAT Plus: Wegovy is among drugs set to be targeted in the next round of Medicare price negotiations, researchers say

Pharma Rachel Cohrs Zhang

STAT Plus: PhRMA scores a small win in legal challenge to Medicare’s drug price negotiation

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharma Jason Mast

STAT Plus: FDA approves first drug for rare neuron disease, Niemann-Pick type C

Pharmalot Ed Silverman

STAT Plus: FTC sues big 3 PBMs for ‘artificially inflated’ insulin prices caused by ‘perverse’ rebating

First Opinion Elizabeth Pfiester

How I fought Big Pharma on insulin prices — and won

Exclusive John Wilkerson

STAT Plus: Cassidy seeks to exempt small biotechs from Medicare drug price negotiation 

Pharmalot Ed Silverman

STAT Plus: FDA cites Granules, a large Indian generic drug manufacturer, for tossing truckloads of key documents

Pharmalot Ed Silverman

STAT Plus: Lawmakers urge U.S. Patent Office and drugmakers to correct patent mistakes

Exclusive Ed Silverman and Michael Nolan

STAT Plus: Inside the quiet strategy pharma giants are using to fend off generics and drive up the cost of medicines

Pharmalot Ed Silverman

STAT Plus: U.S. agency threatens J&J with sanctions if it switches payments to 340B hospitals

Pharmalot Ed Silverman

STAT Plus: Express Scripts sues FTC over a ‘biased’ report about pharmacy benefit managers

Pharma Andrew Joseph

STAT Plus: The news from ESMO: An immunotherapy milestone, studying young-onset cancers, and more

Exclusive Kate Raphael

Pediatricians’ obesity guidelines rest on shaky evidence about eating disorder risks

Pharma Andrew Joseph

STAT Plus: Bristol immunotherapy improves responses in lung cancer, setting up Phase 3 study

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharma Jonathan Wosen

STAT Plus: FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more

The Readout LOUD Adam Feuerstein, Allison DeAngelis, and Elaine Chen

A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more

First Opinion Kendalle Burlin O’Connell

STAT Plus: How to keep the BIOSECURE Act from hobbling U.S. biotech and pharma

Pharmalot Ed Silverman

STAT Plus: FDA scolds AbbVie over ‘misleading’ TV ad for a migraine pill featuring Serena Williams

Health Elaine Chen and Elizabeth Cooney

Obesity drug worked in children ages 6 to 12, study says, raising hopes and concerns

Pharmalot Ed Silverman

STAT Plus: Pharma is still struggling to widen access to medicines — and reach patients — in low- and middle-income countries

Pharma Elisabeth Rosenthal — KFF Health News

STAT Plus: With TV drug ads, what you see is not necessarily what you get

Biotech Matthew Herper

STAT Plus: With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights